Cosentyx is a medication used to treat several inflammatory diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, a monoclonal antibody that targets interleukin-17A, a cytokine involved in the inflammatory response.
According to the provided sources, there is limited information on the adverse effects of Cosentyx in elderly patients. The drug's clinical trials have included patients over the age of 65, but the number of elderly patients in these trials was small [1]. However, the drug has been generally well-tolerated in these trials, with adverse effects being similar to those reported in younger patients [2].
One study published in the Journal of the American Academy of Dermatology analyzed the safety and efficacy of Cosentyx in elderly patients with moderate to severe plaque psoriasis. The study found that the drug was effective in reducing the severity of psoriasis in these patients and was generally well-tolerated. However, the study noted that elderly patients may be more susceptible to infections and should be monitored closely for adverse effects [3].
The prescribing information for Cosentyx lists several potential adverse effects, including infections, allergic reactions, and changes in liver function tests. However, the information does not specifically mention any increased risk of adverse effects in elderly patients [4].
In conclusion, while there is limited information on the adverse effects of Cosentyx in elderly patients, the drug has been generally well-tolerated in clinical trials. However, elderly patients may be more susceptible to infections and should be monitored closely for adverse effects. As with any medication, patients should discuss the risks and benefits of Cosentyx with their healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[3] https://pubmed.ncbi.nlm.nih.gov/29404966/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125504s016lbl.pdf